CEO Cancer Gold Standard™ certification has been awarded to sanofi-aventis, recognizing the company’s commitment to the health of their employees and family members by certifying their efforts to meet an exceptionally high standard of cancer prevention, screening and care guidelines.
William C. Weldon, chairman and chief executive officer of Johnson & Johnson chairs the CEO Roundtable on Cancer, the nonprofit organization of cancer-fighting CEOs who created the CEO Cancer Gold Standard™, in collaboration with the National Cancer Institute, many of its designated cancer centers, the American Cancer Society, Centers for Disease Control and Prevention and leading corporate health professionals.
“Our Gold Standard certification acknowledges the leadership of sanofi-aventis global CEO, Christopher Viehbacher and U.S. President and CEO Gregory Irace and their dedication to fighting cancer, beginning with their own employees and family members,” said Weldon.
The CEO Cancer Gold Standard™, calls for companies to evaluate their benefits and culture and take extensive, concrete actions in five key areas of health and wellness to fight cancer in the workplace. To earn Gold Standard accreditation, a company must establish programs to reduce cancer risk by discouraging tobacco use and encouraging physical activity, healthy diet and nutrition; detect cancer at its earliest stages; and provide access to quality care, including the availability of clinical trials.
The most recent President’s Cancer Panel report, “Maximizing our Nation’s Investment in Cancer: Three Crucial Actions for America’s Health”, identified the CEO Cancer Gold Standard as an initiative that emphasizes cancer screening, tobacco control, cancer education, lifestyle modification, and access to cancer treatment when needed.
Sanofi-aventis becomes the thirty-fourth organization to achieve Gold Standard accreditation. Other organizations championing this workplace-based effort to eliminate cancer as a public health threat include: American Cancer Society, American Legacy Foundation, AstraZeneca, C-Change, CIGNA, Dana-Farber Cancer Institute, Duke Medicine, Edelman, Enzon Pharmaceuticals, GHI, an EmblemHealth company, GlaxoSmithKline, Jenner & Block, Johnson & Johnson, The Lance Armstrong Foundation, MD Anderson Cancer Center, Millennium: The Takeda Oncology Company, Minot State University, H. Lee Moffitt Cancer Center and Research Institute, The National Cancer Institute (NCI), Novartis, The Oncology Nursing Society, OSI Pharmaceuticals, Pfizer, PhRMA, PPD, Quintiles Transnational, SAS Institute, The University of North Dakota, US Oncology, Valeant Pharmaceuticals, Vanderbilt-Ingram Cancer Center, Virtua Health and The Wistar Institute.
About sanofi-aventis
Sanofi-aventis, a leading global pharmaceutical company, discovers, develops and distributes therapeutic solutions to improve the lives of everyone. Sanofi-aventis is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).
William C. Weldon, chairman and chief executive officer of Johnson & Johnson chairs the CEO Roundtable on Cancer, the nonprofit organization of cancer-fighting CEOs who created the CEO Cancer Gold Standard™, in collaboration with the National Cancer Institute, many of its designated cancer centers, the American Cancer Society, Centers for Disease Control and Prevention and leading corporate health professionals.
“Our Gold Standard certification acknowledges the leadership of sanofi-aventis global CEO, Christopher Viehbacher and U.S. President and CEO Gregory Irace and their dedication to fighting cancer, beginning with their own employees and family members,” said Weldon.
The CEO Cancer Gold Standard™, calls for companies to evaluate their benefits and culture and take extensive, concrete actions in five key areas of health and wellness to fight cancer in the workplace. To earn Gold Standard accreditation, a company must establish programs to reduce cancer risk by discouraging tobacco use and encouraging physical activity, healthy diet and nutrition; detect cancer at its earliest stages; and provide access to quality care, including the availability of clinical trials.
The most recent President’s Cancer Panel report, “Maximizing our Nation’s Investment in Cancer: Three Crucial Actions for America’s Health”, identified the CEO Cancer Gold Standard as an initiative that emphasizes cancer screening, tobacco control, cancer education, lifestyle modification, and access to cancer treatment when needed.
Sanofi-aventis becomes the thirty-fourth organization to achieve Gold Standard accreditation. Other organizations championing this workplace-based effort to eliminate cancer as a public health threat include: American Cancer Society, American Legacy Foundation, AstraZeneca, C-Change, CIGNA, Dana-Farber Cancer Institute, Duke Medicine, Edelman, Enzon Pharmaceuticals, GHI, an EmblemHealth company, GlaxoSmithKline, Jenner & Block, Johnson & Johnson, The Lance Armstrong Foundation, MD Anderson Cancer Center, Millennium: The Takeda Oncology Company, Minot State University, H. Lee Moffitt Cancer Center and Research Institute, The National Cancer Institute (NCI), Novartis, The Oncology Nursing Society, OSI Pharmaceuticals, Pfizer, PhRMA, PPD, Quintiles Transnational, SAS Institute, The University of North Dakota, US Oncology, Valeant Pharmaceuticals, Vanderbilt-Ingram Cancer Center, Virtua Health and The Wistar Institute.
About sanofi-aventis
Sanofi-aventis, a leading global pharmaceutical company, discovers, develops and distributes therapeutic solutions to improve the lives of everyone. Sanofi-aventis is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).